Damonapharma
4 employees on LinkedIn · 4 known investors
Find your way into Damonapharma
Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia. Its lead drug targets a specific subunit of the GABA-A receptor to improve neuronal function and reverse cognitive impairment.
Investors · 4
Competitors · 5
by search overlap
Day One Biopharmaceuticals7 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Muna Therapeutics5 shared keywordsMuna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.
Inspirna4 shared keywordsInspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform. The company focuses on common cancers with high unmet need through small molecules and biologics.
Moderna4 shared keywordsModerna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.
Companies competing with Damonapharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Damonapharma do?
- Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia. Its lead drug targets a specific subunit of the GABA-A receptor to improve neuronal function and reverse cognitive impairment.
- Who are Damonapharma's investors?
- Damonapharma's investors include Angelini Ventures, Lumira Ventures, Noetic, Toronto Innovation Acceleration Partners.